Kainova Therapeutics has secured $32m CAD in a Series B financing round to support the clinical development of its immuno-oncology and inflammation pipeline, including multiple GPCR-targeting programmes.

The first close of the financing was led by Investissement Québec, with continued participation from existing investors including CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations and Seido Capital.

Kainova said the funding will be used to accelerate clinical development across its portfolio, with a primary focus on advancing its lead immuno-oncology candidate into later-stage trials.

The company’s most advanced programme, DT-7012, is a Treg-depleting anti-CCR8 antibody currently being evaluated in the ongoing Phase 1/2 Domisol trial in patients with solid tumours. Kainova said the programme targets immunosuppressive regulatory T cells within the tumour microenvironment, an area of increasing interest in cancer immunotherapy research.

In addition to DT-7012, Kainova is developing DT-9081, an EP4 antagonist for solid tumours, and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory indications. All three programmes target G protein-coupled receptors, a drug class with a long history in medicine but growing relevance in immuno-oncology and inflammatory disease.

Sean MacDonald, ceo of Kainova Therapeutics, said the financing supports the company’s strategy of advancing GPCR-based therapies through clinical development. “I am delighted to welcome Investissement Québec as a new investor in the Company and deeply appreciate the continued commitment from our investors,” MacDonald said. “This financing is a strong endorsement of our distinctive scientific strategy, our leadership in GPCR innovation, and our well-defined pipeline of high-value programs with significant commercial potential.”

MacDonald added that securing capital in the current market remains challenging. “Securing this investment is especially significant given the current challenging fundraising environment,” he said, adding that the company remains focused on advancing its clinical pipeline and delivering new treatment options for patients.

Laurence Rulleau, chair of the board at Kainova Therapeutics and managing partner at CTI Life Sciences Fund, said the financing supports both clinical progress and corporate development. “This financing marks a crucial moment in the realization of Kainova Therapeutics’ clinical roadmap and corporate growth,” Rulleau said. “The team achieved significant clinical milestones during 2025, positioning the company at the forefront of GPCR innovation.”

Investissement Québec said its participation reflects a broader commitment to supporting life sciences innovation in the region. Bicha Ngo, ceo of Investissement Québec, said: “Through our participation in this significant financing effort, we are contributing to the relocation of the Company’s headquarters to Québec and laying the groundwork for a team with unique expertise in pharmaceutical development.”

Kainova operates across Montreal, Strasbourg and Boston, and said the Series B financing will also support organisational growth as its programmes progress through clinical development.